Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome

被引:2
|
作者
Kaufmann, Christoph C. [1 ,2 ]
Muthspiel, Marie [1 ,2 ]
Lunzer, Laura [1 ]
Pogran, Edita [1 ,2 ]
Zweiker, David [1 ]
Burger, Achim Leo [1 ,2 ]
Wojta, Johann [3 ,4 ,5 ]
Huber, Kurt [1 ,2 ,3 ]
机构
[1] Klin Ottakring Wilhelminenhosp, 3rd Med Dept Cardiol & Intens Care Med, A-1160 Vienna, Austria
[2] Sigmund Freud Univ, Fac Med, A-1020 Vienna, Austria
[3] Ludwig Boltzmann Inst Cardiovasc Res, A-1090 Vienna, Austria
[4] Med Univ Vienna, Core Facil, A-1090 Vienna, Austria
[5] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
关键词
acute coronary syndrome; myocardial infarction; antiplatelet therapy; anticoagulation; antithrombotic therapy; ELEVATION MYOCARDIAL-INFARCTION; ATRIAL-FIBRILLATION; OPEN-LABEL; TICAGRELOR MONOTHERAPY; ANTITHROMBOTIC THERAPY; CARDIOVASCULAR EVENTS; PLATELET INHIBITION; DE-ESCALATION; INTERVENTION; CLOPIDOGREL;
D O I
10.3390/jcm13082313
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute coronary syndrome (ACS) remains a major challenge in clinical practice, requiring rapid and effective antithrombotic treatment to mitigate adverse ischemic events while minimizing the risk of bleeding. In recent years, results from several clinical trials addressing this issue through various approaches have substantially improved the treatment landscape for patients presenting with ACS. The emergence of new, potent P2Y12 inhibitors has significantly enhanced thrombotic risk reduction and different strategies for de-escalating and shortening dual antiplatelet therapy (DAPT) have demonstrated promising outcomes in reducing bleeding rates. Furthermore, data from ongoing trials focusing on novel therapeutic agents and investigating alternative treatment strategies to optimize outcomes for ACS patients are expected in the next few years. In this review, we summarize the current knowledge and emphasize the critical role of individualized treatment approaches tailored to patient-specific risk factors and individual clinical scenarios.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Emerging Antiplatelet Therapy for Coronary Artery Disease and Acute Coronary Syndrome
    Packard, Kathleen A.
    Campbell, Jennifer A.
    Knezevich, Jon T.
    Davis, Estella M.
    PHARMACOTHERAPY, 2012, 32 (03): : 244 - 273
  • [42] Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention
    Faxon, David P.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2012, 79 (02) : 181 - 197
  • [43] Conversion and outcome of dual antiplatelet therapy after bleeding in patients with acute coronary syndrome
    Ye, Z. S.
    Huang, R.
    Wang, J. I. E.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1429 - 1429
  • [44] Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration
    Olivier, C. B.
    Diehl, P.
    Bode, C.
    Moser, M.
    HERZ, 2014, 39 (07) : 808 - 813
  • [45] Smoking and antiplatelet therapy after acute coronary syndromes
    Flather, Marcus
    Ayton, Sarah
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (06) : 382 - 383
  • [46] Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?
    Darius, Harald
    INTERNIST, 2021, 62 (11): : 1243 - 1252
  • [47] Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention
    Roffman, David S.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (15) : S18 - S24
  • [48] Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
    Cuisset, Thomas
    Deharo, Pierre
    Quilici, Jacques
    Johnson, Thomas W.
    Deffarges, Stephanie
    Bassez, Clemence
    Bonnet, Guillaume
    Fourcade, Laurent
    Mouret, Jean Philippe
    Lambert, Marc
    Verdier, Valentine
    Morange, Pierre Emmanuel
    Alessi, Marie Christine
    Bonnet, Jean Louis
    EUROPEAN HEART JOURNAL, 2017, 38 (41) : 3070 - 3078
  • [49] Oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation after coronary interventions
    Schaefer, A.
    Bauersachs, J.
    HERZ, 2019, 44 (04) : 365 - 378
  • [50] Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review
    Jeffrey B. Washam
    Rowena J. Dolor
    W. Schuyler Jones
    Sharif A. Halim
    Victor Hasselblad
    Stephanie B. Mayer
    Brooke L. Heidenfelder
    Chiara Melloni
    Journal of Thrombosis and Thrombolysis, 2014, 38 : 285 - 298